完整後設資料紀錄
DC 欄位語言
dc.contributor.authorYin, Kai-Haoen_US
dc.contributor.authorHsieh, Yi-Hanen_US
dc.contributor.authorSulake, Rohidas S.en_US
dc.contributor.authorWang, Su-Peien_US
dc.contributor.authorChao, Jui-I.en_US
dc.contributor.authorChen, Chinpiaoen_US
dc.date.accessioned2014-12-08T15:36:55Z-
dc.date.available2014-12-08T15:36:55Z-
dc.date.issued2014-11-15en_US
dc.identifier.issn0960-894Xen_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.bmcl.2014.09.056en_US
dc.identifier.urihttp://hdl.handle.net/11536/25311-
dc.description.abstractThe interactions of gefitinib (Iressa) in EGFR are hydrogen bonding and van der Waals forces through quinazoline and aniline rings. However the morpholino group of gefitinib is poorly ordered due to its weak electron density. A series of novel piperazino analogues of gefitinib where morpholino group substituted with various piperazino groups were designed and synthesized. Most of them indicated significant anti-cancer activities against human cancer cell lines. In particular, compounds 52-54 showed excellent potency against cancer cells. Convergent synthetic approach has been developed for the synthesis of gefitinib intermediate which can lead to gefitinib as well as numerous analogues. (C) 2014 Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.titleOptimization of gefitinib analogues with potent anticancer activityen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.bmcl.2014.09.056en_US
dc.identifier.journalBIOORGANIC & MEDICINAL CHEMISTRY LETTERSen_US
dc.citation.volume24en_US
dc.citation.issue22en_US
dc.citation.spage5247en_US
dc.citation.epage5250en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000343901400023-
dc.citation.woscount0-
顯示於類別:期刊論文